Adding value is at the core of what we do
For patients. For healthcare professionals. For payors.
Who we are
We are a specialty biopharma company committed to bringing innovative, value-added medicines that address the needs of underserved patient populations.
We apply our knowhow and technological innovations to existing pharmaceuticals to unlock their hidden potential and address unmet medical needs. We have built a broad proprietary pipeline of complex value-added products with potential to offer significant advantages over currently available alternatives.
Today, we have two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a novel, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain.
Our development strategy of reformulating and repurposing approved pharmaceuticals primarily utilises the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for which the safety and efficacy have already been established. This focused strategy can dramatically reduce the clinical burden required to bring a product to market, and significantly shortens the development timelines while also reducing costs and risks.
We focus on Value-Added Medicines, Pharma’s Sweet Spot
Stijn Van Rompay
chief executive officer, co-founder and acting chief financial officer
chief business development officer & co-founder
chief operating officer
Koenraad Van der Elst
chief legal officer